Asian Investors Bankroll €40m Promethera Biosciences Series D
Executive Summary
Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.
You may also be interested in...
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
Pipeline Watch: Phase III Starts For Lumasiran, CS1001 And Sepofarsen
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.